7 Investor presentation First three months of 2021 In the last 12 months, Novo Nord the fast-growing US GLP-1 segme US GLP-1 NBRx market share NBRx share 75% 60% 56.4% 58.0% 45% 30% 38.9% 35.6% 15% 12.5% 0% Apr 2020 9.9% Apr 2021 Ozempic ® Rybelsus ® dul Source: NBRx-IQVIA National LRx Monthly, (ending 16 Apr 2021). Each data points represents a rolling four-week average NBRx: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk Note: GLP-1 volume data is monthly volumes; data only available through Mar 2021. Class growth calculated as Q1 2020 vs Q1 2021
Download PDF file